Lipid-lowering Potential of a Complex Dietary Supplement for Cholesterol Control and Vascular Protection
Authors/Creators
- 1. SI «NSC «The M.D. Strazhesko Institute of Сardiology, Clinical and Regenerative Medicine NAMS of Ukraine», Ukraine
Description
The objective: to analyze the lipid-lowering effect of a complex dietary supplement containing red fermented rice extract, bergamot extract and 5-methyltetrahydrofolate in patients with low, moderate and high cardiovascular risk (CVR) or patients who refused to use statins.
Materials and methods. The open-label post-marketing study included 60 patients aged 48.1±0.7 years, 54 (90%) persons of whom were women. According to the results of the assessment of total CVR, most patients were in the low/moderate and high risk categories – 47 (78.3%) and 13 (21.7%) individuals, respectively, the last patients refused to use statins. Overweight and obesity were detected in 50% of the study participants – 24 (40%) and 6 (10%) people with degree I obesity, respectively. Arterial hypertension with a grade 1 increase in blood pressure was present in 45% of the study participants (27 persons, all women).
Patients were prescribed a complex dietary supplement containing red fermented rice extract, bergamot extract, and 5-methyltetrahydrofolate in clearly defined doses for 3 months. At the screening stage and the final visit all patients underwent a general clinical and laboratory examination.
Results. The use of a complex dietary supplement for cholesterol control and vascular protection for 3 months contributed to a decrease in total cholesterol (TC) by 8.1% (p=0.0001), low-density lipoprotein cholesterol (LDL-C) by 14.3% (p=0.0001), non-HDL-C by 12.5% (p=0.0001) and an increase in high-density lipoprotein cholesterol (HDL-C) by 7.1% (p=0.02).
In patients with a baseline triglyceride (TG) level (>1.7 mmol/l), a significant reduction of 18.5% (p=0.04) was found, and in patients with signs of systemic inflammation the level of C-reactive protein (CRP) was >3 mg/ml. The use of a dietary supplement helped to reduce CRP by 33.3% (p=0.008).
Positive dynamics of the albumin to creatinine ratio in patients with more severe albuminuria was determined. The results of the study indicate that the use of a dietary supplement containing red fermented rice extract, bergamot extract and 5-methyltetrahydrofolate does not affect carbohydrate metabolism and liver function tests.
Conclusions. A dietary supplement containing a scientifically based combination of substances of natural origin for the normalization of lipid profile has a positive effect on lipid profile parameters, contributing to a decrease in LDL-C and TG levels in individuals with baseline hypertriglyceridemia and an increase in HDL-C content.
The dietary supplement, which contains red fermented rice extract, bergamot extract and 5-methyltetrahydrofolate, improves endothelial function, as evidenced by a decrease in albuminuria and low-grade systemic inflammation in individuals with higher baseline vaules.
Other
Files
Lipid_lowering_Potential_of_a_Complex_Dietary_Supplement_for_Cholesterol_Control_and_Vascular_Protection.pdf
Files
(1.8 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:28021acb8a06aee40fab684d694ae977
|
1.8 MB | Preview Download |
Additional details
References
- Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337. doi: 10.1093/eurheartj/ehab484.
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. doi: 10.1093/eurheartj/ehz455.
- Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101(12):1689–93. doi: 10.1016/j.amjcard.2008.02.056.
- Banach M, Catapano AL, Cicero AFG, Escobar C, Foger B, Katsiki N, et al. Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel. Pharmacol Res. 2022;183:106370. doi: 10.1016/j.phrs.2022.106370.
- World Health Organization. STEPS study: Prevalence of noncommunicable disease risk factors in Ukraine in 2019 [Internet]. Geneva: WHO; 2020. 66 p. Available from: https://iris.who.int/bitstream/handle/10665/336643/WHOEURO-2020-1468-41218-56059-ukr.pdf?sequence=1&isAllowed=y.
- Gerards MC, Terlou RJ, Yu H, Koks CH, Gerdes VE. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain – a systematic review and meta-analysis. Atherosclerosis. 2015;240(2):415–23. doi: 10.1016/j.atherosclerosis.2015.04.004.
- Banach M, Patti AM, Giglio RV, Cicero AFG, Atanasov AG, Bajraktari G, et al. The Role of Nutraceuticals in Statin Intolerant Patients. J Am Coll Cardiol. 2018;72(1):96–118. doi: 10.1016/j.jacc.2018.04.040.
- Patti AM, Toth PP, Giglio RV, Banach M, Noto M, Nikolic D, et al. Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia. Curr Pharm Des. 2017;23(17):2496–503. doi: 10.2174/1381612823666170317145851.
- Cicero AFG, Fogacci F, Zambon A. Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar. J Am Coll Cardiol. 2021;77(5):620–8. doi: 10.1016/j.jacc.2020.11.056.
- Rahmani P, Melekoglu E, Tavakoli S, Malekpour AN, Rohani P, Sohouli MH. Impact of red yeast rice supplementation on lipid profile: a systematic review and meta-analysis of randomized-controlled trials. Expert Rev Clin Pharmacol. 2023;16(1):73–81. doi: 10.1080/17512433.2023.2138342.
- Minamizuka T, Koshizaka M, Shoji M, Yamaga M, Hayashi A, Ide K, et al. Low dose red yeast rice with monacolin K lowers LDL cholesterol and blood pressure in Japanese with mild dyslipidemia: A multicenter, randomized trial. Asia Pac J Clin Nutr. 2021;30(3):424–35. doi: 10.6133/apjcn.202109_30(3).0009.
- Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, et al. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutr Rev. 2017;75(9):731–67. doi: 10.1093/nutrit/nux047.
- Mollace V, Sacco I, Janda E, Malara C, Ventrice D, Colica C, et al. Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia. 2011;82(3):309–16. doi: 10.1016/j.fitote.2010.10.014.
- Ferrarese I, Lupo MG, Rossi I. Bergamot (Citrus bergamia) peel extract as new hypocholesterolemic agent modulating PCSK9 expression. J Functional Foods. 2023;108(5):105724. doi: 10.1016/j.jff.2023.105724.
- Jin T, Park EY, Kim B, Oh JK. Nonlinear association between serum folate concentrations and dyslipidemia: Korea National Health and Nutrition Examination Survey 2016-2018. Epidemiol Health. 2022;44:e2022046. doi: 10.4178/epih.e2022046.
- Willems FF, Boers GH, Blom HJ, Aengevaeren WR, Verheugt FW. Pharmacokinetic study on the utilisation of 5-methyltetrahydrofolate and folic acid in patients with coronary artery disease. Br J Pharmacol. 2004;141(5):825–30. doi: 10.1038/sj.bjp.0705446.
- Wei Y, Xu B, He Q, Chen P, Zhang Q, Zhang X, et al. Serum total folate, 5-methyltetrahydrofolate and vitamin B12 concentrations on incident risk of lung cancer. Int J Cancer. 2023;152(6):1095–106. doi: 10.1002/ijc.34307.
- The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease. JAMA. 1984;251(3):351–64. doi: 10.1001/jama.1984.03340270029025
- Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. doi: 10.1016/S0140-6736(10)61350-5.
- Li JJ, Lu ZL, Kou WR, Chen Z, Wu YF, Yu XH, et al. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). J Clin Pharmacol. 2009;49(8):947–56. doi: 10.1177/0091270009337509.
- Zhao SP, Liu L, Cheng YC, Shishehbor MH, Liu MH, Peng DQ, et al. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipidlowering mechanisms in patients with coronary heart disease. Circulation. 2004;110(8):915–20. doi: 10.1161/01.CIR.0000139985.81163.CE.
- Zamani M, Rezaiian F, Saadati S, Naseri K, Ashtary-Larky D, Yousefi M, et al. The effects of folic acid supplementation on endothelial function in adults: a systematic review and dose-response meta-analysis of randomized controlled trials. Nutr J. 2023;22(1):12. doi: 10.1186/s12937-023-00843-y.
- Doshi SN, McDowell IF, Moat SJ, Payne N, Durrant HJ, Lewis MJ, et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation. 2002;105(1):22–6. doi: 10.1161/hc0102.101388.
- Calabrò A, Bagnato C, Cerchiaro A, Chiera S, Rosselli C, Palaia G, et al. Anti-Inflammatory Effects of Bergamot on the Elderly: A Literature Review. Acta Sci Nutritional Health. 2023;7(10):48–55. doi: 10.31080/ASNH.2023.07.1310.
- Mollace R, Gliozzi M, Tavernese A. Bergamot Polyphenolic Fraction supplementation improves metabolic balance, endothelial function and maximal oxygen uptake in athletes. J Sports Med Ther. 2018;3:053–061. doi: 10.29328/journal.jsmt.100102.